What Causes False CA19-9 Results?
False CA19-9 elevations occur primarily due to benign conditions (biliary obstruction, inflammatory hepatobiliary disease, hydronephrosis with infection), genetic inability to produce the antigen (Lewis ab genotype), and laboratory interference from heterophilic antibodies.
Genetic Causes
- Lewis ab genotype (5% of population): These patients genetically cannot synthesize CA19-9 antigen since it exists as an epitope of sialylated Lewis A blood group antigen. CA19-9 testing should not be attempted in this population as results will be falsely low or undetectable 1.
Benign Clinical Conditions
The ASCO guidelines clearly establish that CA19-9 lacks specificity for malignancy and is elevated in numerous benign conditions 1:
Hepatobiliary Causes
- Biliary obstruction (both malignant and benign)
- Inflammatory conditions of the hepatobiliary system
- Cholangitis
Renal Causes
- Benign hydronephrosis, particularly when associated with:
- Bilateral involvement
- Urinary tract infection
- Proteinuria
- Elevated blood urea nitrogen
- Severe urinary tract obstruction
- High-grade hydronephrosis
In one study, 25% of patients with benign hydronephrosis had CA19-9 >37 U/mL versus only 1.8% without hydronephrosis 2.
Other Benign Conditions
- Thyroid disease
- Various inflammatory conditions 1
Laboratory Interference
Recent case reports (2024-2025) have identified heterophilic antibodies as a significant cause of false CA19-9 elevation 3, 4, 5:
Key Features of Heterophilic Antibody Interference:
- Patients show markedly elevated CA19-9 without clinical manifestations
- Results vary dramatically between different analyzer systems
- Most commonly affects electrochemiluminescence immunoassay platforms
Detection Methods:
- Polyethylene glycol (PEG) precipitation: Reduces CA19-9 concentration if interference present 4, 5
- Heterophilic antibody blocking assays (HBT-6, HBT-1): Confirm interference 5
- Testing on multiple analyzer systems: Different platforms show discordant results 5
- Gradient dilution studies: Non-linear dilution suggests interference
Medication-Related Causes
- Polaprezinc (zinc-carnosine compound): One case report documented false CA19-9 elevation from 18.9 to 1,699.4 U/mL after polaprezinc administration for chemotherapy-induced dysgeusia, which resolved upon discontinuation 6.
Clinical Pitfalls to Avoid
When CA19-9 is elevated without corresponding clinical or imaging findings:
- First, verify the patient is not Lewis ab genotype
- Evaluate for benign causes (check for biliary obstruction, hydronephrosis, infection)
- Suspect heterophilic antibody interference and request:
- PEG precipitation testing
- Retesting on alternative analyzer platform
- Heterophilic antibody blocking assay
Critical caveat: The ASCO guidelines emphasize that CA19-9 elevations alone cannot provide definitive evidence of disease and require confirmation with imaging studies and/or biopsy 1. This applies equally to ruling out false elevations—clinical correlation is mandatory.